Sekhmet Pharmaventures
Gamot API is the holding company of Sekhmet Pharmaventures Pvt. Ltd. Asian private equity major PAG has formed an investment platform called Gamot API Pte. Ltd. based in Singapore, along with Indian private equity firms, CX Partners and Samara Capital, to buy stakes in fast-growing Indian pharma companies. The Indian subsidiary of Gamot API is known as Sekhmet Pharmaventures Pvt. Ltd.
Sekhmet Pharmaventures has acquired major stake in Chennai-based Anjan Drug Pvt. Ltd. in October 2020. Subsequently, Sekhmet Pharmaventures acquired major stake in Optimus Drugs Group of Companies in May 2022. The Company plans to invest in multiple manufacturing facilities dedicated to Active Pharmaceutical Ingredients and formulations, as India is expected to become an important part of the global supply chain, amid changing geopolitical dynamics.
PAG is one of Asia’s leading investment firms, having a world-class platform and an unparalleled network of local, experienced investment professionals. PAG manages US$45 billion in capital across strategies including private equity, real estate and absolute returns. Some of PAG’s past investments include Sinopharm, Alphamab Oncology, Cushman & Wakefield, Universal Studios, Japan, Hisun Bioray and Tencent Music Entertainment.

CX Partners is a private equity group in the Indian mid-market, with a track record of delivering returns through cycles. CX Partners has invested in diversified sectors which include companies such as Thyrocare, Natco Pharma, Sutures India, Barbeque Nation, Security & Intelligence Services and NTL Electronics.
Samara Capital is private equity firm with strong operating capabilities, focus on long term business ownership and value creation, while driving positive impact for all stakeholders. Some of the investments made by Samara Capital in the past include More retail, Sapphire foods, Monte Carlo fashions, Lotus Surgicals, AIG Hospitals, RBL Bank and Oilmax Energy.
Anjan Drug
Part of the platform since Oct 2020
Anjan Drug Private Limited was founded in 1990 by Mr. C Kalaichelvan. Anjan has grown into a fully integrated Pharmaceutical API manufacturing Organization, backed with immense experience in development and manufacturing.
Anjan is one of India’s leading manufacturers of unique Active Pharmaceutical Ingredients (API). Since its inception in 1990, Anjan Drug Private Limited has achieved the potential to deliver over a minimum of one ton measure of unique active ingredient in just 24 hours. This clearly reflects the trust our partners who in turn, are world class players in the pharmaceutical world have in our capability and quality performance. Adhering to stringent GMP guidelines, Anjan’s products hold USDMF, TGA & EuCOS approvals, clearly ensuring its supreme quality of its products.

Optimus Pharma
Part of the platform since May 2022
Optimus is one of the fastest-growing pharmaceutical companies with market presence since 2004 in providing the best quality of API, Intermediates & Finished formulations in Global markets. Their aim from day one has been to provide and ensure better healthcare across the globe through their research, Innovations, affordable products & manufacturing excellence.
Optimus was established in 2004 by a team of scientists who had a passion for chemistry and ensuring better healthcare for everyone. In their journey of more than a decade, they have developed many niche molecules and have emerged as one of the reputed manufacturing companies in the industry. Their determination has driven us from a development lab to a commercial scale Intermediates/ APIs /Finished dosages manufacturing company. Their strength lies in strong process chemistry, process engineering, and focus on R&D which enabled them to meet the global pharma requirements. They believe their human resource is their best competency and are dedicated and determined for the betterment of the organization. As a rapidly growing company, they ensure, respect, and strictly implement the “SHE” policy.

Our Policies
Company Policies
August 2, 2024
Customer Health & Safety Policy
July 24, 2024
Code of Conduct
July 2, 2024
Sustainability Policy
June 11, 2024
Occupational Health and Safety Policy
May 30, 2024
Corporate Social Responsibility Policy
May 20, 2024
Human Rights Policy
April 2, 2024
Supplier Code of Conduct
March 4, 2024
Board Diversity Policy
February 12, 2024
Whistleblower Policy
January 2, 2024
Equal Opportunity Employer and Anti-Harassment Policy
June 2, 2023